



GUJARAT TERCE LABORATORIES LIMITED

Statement of Unaudited Standalone Financial Results for the Quarter Ended 30/06/2026 [Rs.In Lakhs except per share detail]					
Particulars		Quarter ended			Year ended
		30-06-2026 Unaudited	31-03-2026 Audited	30-06-2025 Unaudited	31-03-2026 Audited
1		2	3	4	5
I.	Revenue from operations	900.24	1139.93	1085.36	4747.27
II.	Other income	48.23	7.66	9.48	34.04
III.	Total Revenue (I+II)	948.47	1147.59	1094.84	4781.31
IV.	Expenses:				
	a) Cost of Material consumed	13.51	70.79	198.38	607.49
	b) Purchase of stock in trade	256.13	330.90	258.99	1148.07
	c) Changes in inventories of finished goods, WIP and stock in trade.	52.87	-12.37	-15.31	-42.15
	d) Employees benefits expenses.	372.64	411.88	374.86	1606.63
	e) Finance Costs	3.24	2.53	4.93	17.95
	f) Depreciation and amortisation exp.	10.57	13.43	9.61	42.27
	g) Other Expenses	254.39	264.57	270.48	1052.43
	Total Expenses	963.35	1081.73	1101.94	4432.69
V	Profit/(Loss) before exceptional and Extra ordinary items and Taxes.(III - IV)	-14.88	65.86	-7.10	348.62
VI	Exceptional items.	0.00	45.39	0.00	45.39
VII	Profit/(Loss) before extraordinary items and Tax (V-VI)	-14.88	20.47	-7.10	303.23
VIII	Extraordinary items	0.00	0.00	0.00	0.00
IX	Profit/(Loss) before Tax (VII-VIII)	-14.88	20.47	-7.10	303.23
X	Tax Expenses				
	1) Current Tax	0.00	31.07	0.00	108.78
	2) Deferred Tax	2.93	-20.70	-2.75	-25.72
	3) Income-Tax of Earlier Year(refer Note 4)	0.00	0.00	0.00	0.00
XI	Profit/(Loss) for the period from continuing operations (IX-X)	-17.81	10.10	-4.35	220.17
XII	Other Comprehensive Income				
	Re-measurement losses on post employment defined benefit plans	0.00	0.00	0.00	0.00
	Income Tax effect	0.00	0.00	0.00	0.00
	Total	0.00	0.00	0.00	0.00
	Net loss/(gain) on Fair Value through OCI (FVTOCI) on equity securities	0.00	0.00	0.00	0.00
XIII	Other Comprehensive Income for the period, net of tax	0.00	0.00	0.00	0.00
XIV	Total Comprehensive Income for the period (XI+XII)	-17.81	10.10	-4.35	220.17
XV	Paid up Equity Capital (at par value of Rs. 10 each)	779.13	779.13	742.03	779.13
XVI	Earning per equity share				
	a) Basic	-0.23	0.13	-0.06	2.92
	b) Diluted	-0.23	0.13	-0.06	2.92
	(See accompanying notes to the Financial Results)				
Place:Ahmedabad		For Gujarat Terce Laboratories Limited  Aalap Prajapati Managing Director & CEO DIN: 08088327			
Date:07/08/2026					
					
Notes:					
1	The above Unaudited Financial Results have been reviewed by the Audit Committee and thereafter approved by the Board of Directors at their meeting held on August 07, 2026				
2	The Limited Review for the quarter ended 30.06.2026 has been carried out by the statutory auditor, as required under Regulation 33 of SEBI (LODR) Regulation, 2015.				
3	The Company has adopted Indian Accounting Standard ("Ind AS") notified by the Ministry of Corporate Affairs with effect from April 01, 2017 and accordingly these Unaudited financial results of the company for the quarter ended 30.06.2026 has been prepared in accordance with the Indian Accounting Standards ("Ind AS") as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder.				
4	The Company is operating in single (Pharmaceutical) segment, so above Unaudited Financial Results are for single segment only.				
5	The figures of the previous quarter / periods has been regrouped/reclassified, wherever necessary.				